Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
122 participants
INTERVENTIONAL
2020-08-01
2021-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nurse-led disease management education
Individual patient education was provided, and patients were followed up by telephone at two-week intervals beginning the week after their clinic visit.
Nurse-led disease management education
Nurse-led disease management education was applied to the intervention group
Control Group
No interventions were performed other than routine clinical procedures.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nurse-led disease management education
Nurse-led disease management education was applied to the intervention group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a clinical diagnosis AS according to the modified New York criteria
* Receiving TNF-α inhibitor treatment.
Exclusion Criteria
* Illiterates
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zeliha Tülek
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zeliha Tülek
RN, Prof
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ayten Dağ, RN, PhD
Role: PRINCIPAL_INVESTIGATOR
Istanbul University - Cerrhapasa
Zeliha Tulek, RN, Prof
Role: STUDY_DIRECTOR
Istanbul University - Cerrhapasa
Emire Seyahi, MD, Prof
Role: STUDY_CHAIR
Istanbul University - Cerrhapasa
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istanbul University-Cerrahpasa Cerrahpasa Medical Faculty Hospital
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Duruoz MT, Doward L, Turan Y, Cerrahoglu L, Yurtkuran M, Calis M, Tas N, Ozgocmen S, Yoleri O, Durmaz B, Oncel S, Tuncer T, Sendur O, Birtane M, Tuzun F, Bingol U, Kirnap M, Celik Erturk G, Ardicoglu O, Memis A, Atamaz F, Kizil R, Kacar C, Gurer G, Uzunca K, Sari H. Translation and validation of the Turkish version of the Ankylosing Spondylitis Quality of Life (ASQOL) questionnaire. Rheumatol Int. 2013 Nov;33(11):2717-22. doi: 10.1007/s00296-013-2796-y. Epub 2013 Jun 14.
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994 Dec;21(12):2286-91.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Disease management in AS
Identifier Type: -
Identifier Source: org_study_id